CAPTION: For the treatment of certain types of brain tumors, IORT with the Xoft System may allow appropriately selected patients to potentially replace weeks of postoperative external beam radiation therapy (EBRT) with 1 fraction of radiation.
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, has announced that the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. This procedure is the start of a clinical trial on IORT for patients with large brain metastases treated with neurological resection with the Xoft System, led by Shiao Yuo Woo, MD, FACR, radiation oncologist, James Graham Brown Cancer Center at the University of Louisville.1
"We are very excited to open this clinical trial, and hope our results show intraoperative balloon-based brachytherapy is both well-tolerated and effective for sterilizing subclinical disease in the tumor bed after resection of large brain metastases,” said Mehran Yusuf, MD, radiation oncologist, James Graham Brown Cancer Center at the University of Louisville. “This project would not have been possible without the support and coordination of an excellent team of neurosurgeons, radiation oncologists, medical physicists, clinical research staff within the University of Louisville Health, and continued support from Xoft.”
The Xoft System is also currently being studied for the treatment of other types of brain tumors in leading institutions worldwide, including the European Medical Center, one of the largest private medical clinics in Russia and an international leader in comprehensive care and oncology. Positive preliminary clinical data on Xoft IORT for the treatment of recurrent glioblastoma (GBM) was presented at the European Association of Neurosurgical Societies (EANS) Congress in Dublin, Ireland in September 2019 by Alexey Gaytan, MD, PhD, neurosurgeon at the European Medical Center in Moscow, Russia. In a matched pair study, 30 patients were treated for recurrent GBM. The IORT group (A) was treated with a single fraction of radiation immediately following surgical resection, without chemotherapy or temozolomide following surgery. The comparison group (B) was treated with routine postoperative adjuvant chemotherapy +/- concomitant or sequential EBRT. Median overall survival (OS) in group A was 24 months; OS for group B was 21 months. As of September 2019, nine patients were still alive from group A, whereas none of the patients in group B survived.
A retrospective analysis published in World Neurosurgery by Alexey Krivoshapkin, MD, PhD, et al. examined the repeat resection and the various methods of IORT for the treatment of malignant brain gliomas (MBGs), including high-energy linear accelerators and modern, integrated brachytherapy solutions using solid and balloon applicators.2 The findings from this review showed IORT with balloon applicators to be particularly promising.
Worldwide, almost 297,000 cases of brain and nervous system tumors are diagnosed per year.3 GBM is the most common and aggressive type of malignant primary brain tumor, with a median survival of 10-12 months.4,5 Treatment for brain tumors typically involves surgical removal, followed by radiation therapy or chemotherapy.
The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. IORT with the Xoft System allows radiation oncologists and surgeons to work together to deliver a full course of radiation treatment in one day, at the time of surgery, while the patient is under anesthesia. Once the tumor has been surgically removed, the Xoft System’s miniature x-ray source is inserted inside a flexible balloon-shaped applicator, which is then placed inside the tumor cavity, filled with saline, and used to deliver a single dose of radiation directly to the tumor bed. For the treatment of certain types of brain tumors, IORT with the Xoft System may allow appropriately selected patients to potentially replace weeks of post-operative external beam radiation therapy (EBRT) with a single fraction of radiation.
“Brain IORT with the Xoft System is a groundbreaking procedure that has potential to extend lives and address a significant unmet need in the treatment of several types of cancers including metastatic brain tumors and GBM,” according to Michael Klein, Chairman and CEO of iCAD. “This promising treatment option may improve outcomes and quality of life for patients, with a shorter treatment duration and minimal side effects compared to EBRT, which involves weeks of daily radiation treatments. This is a significant milestone for iCAD and represents just one of the exciting new and emerging applications we are currently exploring with the Xoft System, and we look forward to partnering with additional prominent investigators as our research continues.”
First brain tumor treated in U.S. with iCAD's Xoft IORT . Appl Rad Oncol.